{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:52Z","timestamp":1792801912496,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The clinical standard practice of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 therapy is a single injection per treatment cycle, with 6 weeks between cycles. While clinical schedules currently utilize single-bolus cycles, splitting a treatment cycle into multiple smaller injections has demonstrated benefits in other radionuclide therapies, preclinically and in clinical studies. Potential mechanisms for improved therapeutic efficacy include receptor recycling, receptor upregulation, or targeting new cell growth between fractions. This study aims to investigate the effects on tumor size and animal survival, in a mouse model of prostate cancer, of fractionating [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 therapy compared to the same total activity in a single injection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BALB\/c mice bearing subcutaneous LNCaP prostate cancer tumors, below 650 mm\n                      <jats:sup>3<\/jats:sup>\n                      in volume, were treated with either 1\u2009\u00d7\u200930 MBq, 2\u2009\u00d7\u200915 MBq (24-hour window), or 2\u2009\u00d7\u200915 MBq (6-day window). SPECT\/CT imaging showed a higher, but not significantly so, tumor uptake in the 24-hour window group than in the unfractionated one. Differences in tumor sizes were primarily visible during regrowth after therapy, with significantly smaller relative tumor sizes in the 24-hour window group compared to the unfractionated group day 89\u201395 post inoculation. The median survival for the 24-hour group (71.5 days) was significantly longer than that of the unfractionated group (46 days;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024). The 6-day group tumor sizes and survival came close to the 24-hour one, but was not significantly better than the unfractionated group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study demonstrates that fractionation gives therapeutic benefit in an animal model of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 therapy of prostate cancer for tumors in this size range. A shorter 24-hour window outperformed a longer of 6 d between fractions. The outlook for clinical translation will depend on if the mechanism is relevant at conditions, blood ligand concentration etc., that differs between the animal model and human patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01417-9","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:23:43Z","timestamp":1774427023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fractionation gives therapeutic benefit in animal model of [177Lu]Lu-PSMA-617 therapy of prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Oskar Vilhelmsson","family":"Timmermand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"\u00d6stholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahed","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Altai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-5915","authenticated-orcid":false,"given":"Anders","family":"\u00d6rbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023;29:1651\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2875.","journal-title":"Clin Cancer Res"},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/cncr.10304","volume":"94","author":"GL DeNardo","year":"2002","unstructured":"DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O\u2019Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94:1332\u201348. https:\/\/doi.org\/10.1002\/cncr.10304.","journal-title":"Cancer"},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/cancers14010235","volume":"14","author":"M Elvborn","year":"2022","unstructured":"Elvborn M, Shubbar E, Forssell-Aronsson E. Hyperfractionated Treatment with Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model. Cancers (Basel). 2022;14:235. doi:ARTN 235.","journal-title":"Cancers (Basel)"},{"key":"1417_CR5","unstructured":"3390\/cancers14010235."},{"key":"1417_CR6","doi-asserted-by":"publisher","first-page":"e31409","DOI":"10.1016\/j.heliyon.2024.e31409","volume":"10","author":"A Romiani","year":"2024","unstructured":"Romiani A, Simonsson K, Pettersson D, Al-Awar A, Rassol N, Bakr H, et al. Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice. Heliyon. 2024;10:e31409. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31409.","journal-title":"Heliyon"},{"key":"1417_CR7","first-page":"242076","volume":"65","author":"G Costa","year":"2024","unstructured":"Costa G, Orlov C, Yousefzzadeh-Nowshahr E, Fitzpatrick K, Frey K, Beer A, et al. 68Ga-PSMA Receptor Saturation During Radioligand Therapy: Assessment Using a PBPK Model. J Nucl Med. 2024;65:242076.","journal-title":"J Nucl Med"},{"key":"1417_CR8","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125:2561\u20139. https:\/\/doi.org\/10.1002\/cncr.32072.","journal-title":"Cancer"},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1634\/theoncologist.2020-0028","volume":"25","author":"MJ Niaz","year":"2020","unstructured":"Niaz MJ, Batra JS, Walsh RD, Ramirez-Fort MK, Vallabhajosula S, Jhanwar YS, et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2020;25:477\u2013e895. https:\/\/doi.org\/10.1634\/theoncologist.2020-0028.","journal-title":"Oncologist"},{"key":"1417_CR10","doi-asserted-by":"publisher","unstructured":"Tagawa ST, Thomas C, Nauseef JT, Sartor AO, Sun MP, Castellanos SH et al. Final results of a phase I\/II dose-escalation study of fractionated dose Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:5074. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5074","DOI":"10.1200\/JCO.2024.42.16_suppl.5074"},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10967-024-09845-4","volume":"334","author":"XB Zheng","year":"2025","unstructured":"Zheng XB, Cui B, Hou WL, Zhao ZQ, He SH, Li X, et al. The additive value of fractionated Lu-PSMA-617 administration in treating prostate cancer. J Radioanal Nucl Ch. 2025;334:99\u2013104. https:\/\/doi.org\/10.1007\/s10967-024-09845-4.","journal-title":"J Radioanal Nucl Ch"},{"key":"1417_CR12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270444","author":"AJK Hoyvik","year":"2025","unstructured":"Hoyvik AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, Peng Q, Wangen-Riise R, et al. Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.125.270444.","journal-title":"J Nucl Med"},{"key":"1417_CR13","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.tranon.2022.101450","volume":"22","author":"TM Jeitner","year":"2022","unstructured":"Jeitner TM, Babich JW, Kelly JM. Advances in PSMA theranostics. Transl Oncol. 2022;22:101450. https:\/\/doi.org\/10.1016\/j.tranon.2022.101450.","journal-title":"Transl Oncol"},{"key":"1417_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13550-022-00935-6","volume":"12","author":"C Meyer","year":"2022","unstructured":"Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, et al. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022;12:65. https:\/\/doi.org\/10.1186\/s13550-022-00935-6.","journal-title":"EJNMMI Res"},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","volume":"7","author":"CA Umbricht","year":"2017","unstructured":"Umbricht CA, Bene\u0161ov\u00e1 M, Schmid RM, T\u00fcrler A, Schibli R, van der Meulen NP, et al. (44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617-preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617. EJNMMI Res. 2017;7:9. https:\/\/doi.org\/10.1186\/s13550-017-0257-4.","journal-title":"EJNMMI Res"},{"key":"1417_CR16","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","volume":"28","author":"B Sheehan","year":"2022","unstructured":"Sheehan B, Neeb A, Buroni L, Paschalis A, Riisnaes R, Gurel B, et al. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clin Cancer Res. 2022;28:3104\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4531.","journal-title":"Clin Cancer Res"},{"key":"1417_CR17","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/thno.93249","volume":"14","author":"D Arbuznikova","year":"2024","unstructured":"Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla L-C, Steinacker N, Mix M, et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [<\u2009sup>177\u2009Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 2024;14:2560\u201372. https:\/\/doi.org\/10.7150\/thno.93249.","journal-title":"Theranostics"},{"key":"1417_CR18","doi-asserted-by":"publisher","unstructured":"Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022;15. https:\/\/doi.org\/10.3390\/ph15101292.","DOI":"10.3390\/ph15101292"},{"key":"1417_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Stuparu AD, Evans-Axelsson S, L\u00fcckerath K, Wei L, Kim W, et al. Establishing\u2009<\u2009sup>177\u2009Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. J Nucl Med. 2017;58:1786\u201392. https:\/\/doi.org\/10.2967\/jnumed.117.193359.","journal-title":"J Nucl Med"},{"key":"1417_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mc.23360","volume":"61","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Young KH. Effects of radiation on tumor vasculature. Mol Carcinog. 2022;61:165\u201372. https:\/\/doi.org\/10.1002\/mc.23360.","journal-title":"Mol Carcinog"},{"key":"1417_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/cbr.2024.0170","volume":"40","author":"A \u00d6rbom","year":"2025","unstructured":"\u00d6rbom A, Strand J, Altai M, Zedan W, Kristiansson A, Ceder J, et al. Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer. Cancer Biother Radiopharm. 2025;40:219\u201327. https:\/\/doi.org\/10.1089\/cbr.2024.0170.","journal-title":"Cancer Biother Radiopharm"},{"key":"1417_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2967\/jnumed.124.268457","volume":"66","author":"NRR Zaid","year":"2025","unstructured":"Zaid NRR, Bastiaannet R, Hobbs R, Sgouros G. Mathematic Modeling of Tumor Growth During [Lu]Lu-PSMA Therapy: Insights into Treatment Optimization. J Nucl Med. 2025;66:84\u201390. https:\/\/doi.org\/10.2967\/jnumed.124.268457.","journal-title":"J Nucl Med"},{"key":"1417_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2967\/jnumed.120.254516","volume":"62","author":"N Yusufi","year":"2021","unstructured":"Yusufi N, Wurzer A, Herz M, D\u2019Alessandria C, Feuerecker B, Weber W, et al. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using. J Nucl Med. 2021;62:1106\u201311. .3 and <\u2009sup>177\u2009Lu-PSMA I&T","journal-title":"J Nucl Med"},{"key":"1417_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2967\/jnumed.124.268508","volume":"66","author":"C Foxton","year":"2025","unstructured":"Foxton C, Waldron B, Veggerby Gr\u00f8nlund R, Sim\u00f3n J, Cornelissen B, O\u2019Neill E, et al. Preclinical Evaluation of <\u2009sup>177\u2009Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy. J Nucl Med. 2025;66:599\u2013604. https:\/\/doi.org\/10.2967\/jnumed.124.268508.","journal-title":"J Nucl Med"},{"key":"1417_CR25","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330. https:\/\/doi.org\/10.1007\/s00259-019-04345-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1417_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.bjc.6600119","volume":"86","author":"HK Awwad","year":"2002","unstructured":"Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer. 2002;86:517\u201323. https:\/\/doi.org\/10.1038\/sj.bjc.6600119.","journal-title":"Br J Cancer"},{"key":"1417_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fendo.2018.00247","volume":"9","author":"CH Lo","year":"2018","unstructured":"Lo CH, Lynch CC. Multifaceted roles for macrophages in prostate cancer skeletal metastasis. Front Endocrinol (Lausanne). 2018;9:247.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1417_CR28","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015;56:1697\u2013705. https:\/\/doi.org\/10.2967\/jnumed.115.161299.","journal-title":"J Nucl Med"},{"key":"1417_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s11307-021-01600-5","volume":"23","author":"MA Lodge","year":"2021","unstructured":"Lodge MA, Solnes LB, Chaudhry MA, Wahl RL. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of (68)Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy. Mol Imaging Biol. 2021;23:766\u201374. https:\/\/doi.org\/10.1007\/s11307-021-01600-5.","journal-title":"Mol Imaging Biol"},{"key":"1417_CR30","doi-asserted-by":"publisher","first-page":"e0307558","DOI":"10.1371\/journal.pone.0307558","volume":"19","author":"D Roth","year":"2024","unstructured":"Roth D, Safi M, Vilhelmsson Timmermand O, Sereti E, Molendowska M, Gottschalk M, et al. Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting. PLoS ONE. 2024;19:e0307558. https:\/\/doi.org\/10.1371\/journal.pone.0307558.","journal-title":"PLoS ONE"},{"key":"1417_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2967\/jnumed.109.065706","volume":"51","author":"M de Jong","year":"2010","unstructured":"de Jong M, Maina T. Of mice and humans: are they the same?>--Implications in cancer translational research. J Nucl Med. 2010;51:501\u20134. https:\/\/doi.org\/10.2967\/jnumed.109.065706.","journal-title":"J Nucl Med"},{"key":"1417_CR32","doi-asserted-by":"publisher","unstructured":"Vorster M, Mallum A, Sathekge M, Pascual T. Considering the Costs of Targeted Radionuclide Therapies in Prostate Cancer. Med Res Archives. 2024;12. https:\/\/doi.org\/10.18103\/mra.v12i3.5043.","DOI":"10.18103\/mra.v12i3.5043"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01417-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:50:10Z","timestamp":1781643010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01417-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with ARRIVE guidelines and national legislation on laboratory animal protection and permitted by the local Ethics Committee for Animal Research at Lund University (Dnr: 04350\u2009\u2212\u20092020, Dnr 5.8.18\u201307300\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}